medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2021, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2021; 37 (3)

Acute myeloid leukemia: prognostic influence of some biomarkers and the therapeutic response in patients under 60 years of age

Quintero SY, Hernández PC, Concepción FY

Language: Spanish
References: 45
Page: 1-23
PDF size: 557.92 Kb.


ABSTRACT

Introduction: Acute myeloid leukemia is a clonal disease, recognized as one of the most heterogeneous malignant hemopathy in which certain clinical, immunological, cytogenetic and molecular biomarkers influence the response of patients to treatment.
Objective: Describe the prognostic influence of immunological, cytogenetic and molecular biomarkers on the therapeutic response in adult patients under 60 years of age with acute myeloid leukemia.
Methods: An exhaustive review was conducted about the topic in the databases as Pubmed, Scielo, ScienceDirect, Medline and Scholar Google, for which papers mainly published in the last five years were used as reference.
Analysis and synthesis of the information: The immunological, cytogenetic and molecular heterogeneity of adult patients under 60 years of age with acute myeloid leukemia is related to the variability in the response to treatment that patients have and affects their overall and disease-free survival.
Conclusions: Based on the immunological, cytogenetic and molecular characteristics, it is possible to establish the prognosis of patients with acute myeloid leukemia, which allows selecting the appropriate therapy to reduce complications, relapses as much as possible and increase overall survival.


REFERENCES

  1. Almeida AL, Azevedo IC, Carvalho DP,Vitor AF, Santos VE, Ferreira MA. Clinical and epidemiological aspects of leukemias. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2017 [acceso: 18/12/2019];33(2). Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/511

  2. Virchow R. Weisses Blut. Neue Notizen aus Gebiete der Natur- und Heilkunde. 1845;36:11151-6.

  3. Seufert W, Seufert WD. The recognition of leukemia as a systemic disease. J Hist Med Allied Sci. 1982;37: 4-50.

  4. Virchow R. Die Leukämie. In: Virchow R, editor. Gesammelte Abhandlungenzur Wissenschaftlichen Medizin. Frankfurt: Meidinger;1856. p.190.

  5. Ebstein W. Ueberdie acute Leukämie und Pseudoleukämie. Deutsch Arch Klin Med. 1889;44:343.

  6. Naegeli O. Überrothes Knochenmark und Myeloblasten. Deutsch Med Wochenschr. 1900;26:287.

  7. Liesveld JL, Lichtman MA. Acute Myelogenous Leukemia. In: William´s Hematology. 10th ed. New York: McGraw-Hill. 2021. p.2845-3017.

  8. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al (eds). SEER Cancer Statistics Review, 1975-2017. National Cancer Institute. Bethesda, MD. [based on November 2019 SEER data submission, posted to the SEER web site, April 2020] [acceso: 18/12/2019]. Disponible en: http://seer.cancer.gov/csr/1975_2017/

  9. National Cancer Institute. SEER Cancer Stat Facts: Acute Myeloid Leukemia. May 2017[acceso: 12/06/2018]. Disponible en: https://seer.cancer.gov/statfacts/html/amyl.html

  10. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(r)) Acute Myeloid Leukemia Version 1.2017-February 24 2017.NCCN.org

  11. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021 Jan;71(1):7-33. DOI: https://10.3322/caac.21654

  12. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20): 2391-405.

  13. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209-21.

  14. Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018; 93: 1267267-1291. DOI: https://doi.org/10.1002/ajh.25214

  15. Repp R, Schaekel U, Helm G, Thiede C, Soucek S, Pascheberg U, et al. Immunophenotyping is an independent factor for risk stratificartion in AML. Cytometry.2003; 53B:11-9.

  16. Derolf AR, Bj?rklund E, Mazur J, Bj?rkholm M, Porwit A. Expression patterns of CD33 and CD15 predict outcome in patients with acute myeloid leukemia. Leuk Lymph. 2008; 49:1279-91.

  17. Haubner S, Perna F, K?hnke T, Schmidt C, Berman S, Augsberger C, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64-74.

  18. Roshal M, Chien S, Othus M, Madera BL, Fang M, Appelbaum FR, et al. The proportion of CD34+CD38low or neg myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia. Leukemia. 2013;27:728-31. DOI: https://10.1038/leu.2012.217

  19. Schuurhuis GJ, Heuser M, Freeman S, Bené MCh, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European Leukemia Net MRD Working Party. Blood. 2018;131:1275-91.

  20. D?hner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136-52.

  21. Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica. 2002; 87:250-6.

  22. Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Hinai A, Zeilemaker A, et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med. 2018; 378:1189-99.

  23. Medinger M, Passweg JR. Acute myeloid leukaemia genomics. Br J Haematol. 2017; 179(4):530-42. DOI: https://10.1111/bjh.14823

  24. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92(7):2322-33.

  25. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-83.

  26. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-36..

  27. D?hner H, Estey EH, Amadori S, Appelbaum FR, B?chner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010; 115:453-74

  28. D?hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international panel. Blood. 2017;129(4):424-47.

  29. Quintero Y, Concepción Y, Hernández C, Romero A, Macia I, Lam RM. Supervivencia de pacientes adultos con leucemia mieloide aguda no promielocítica tratados con altas dosis de antraciclinas. Rev Cub Hematol Inmunol Hemoter. 2020;36(1):e1105.

  30. McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, et al: Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9:1050-63.

  31. Patel SS, Kuo FC, Gibson ChJ, Steensma DP, Soiffer RJ, Alyea EP, et al. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in the novo AML. Blood. 2018;131(25):2816-25. Disponible en https://doi.org/10.1182/blood-2018-01-828467.

  32. Lagunas-Range FA, Pérez-Contreras VA, Cortés-Penagos C. FLT3, NPM1 y C/EBPa como marcadores de pronóstico en pacientes con leucemia mieloide aguda. Rev Hematol Mex.2015;16:152-67.

  33. Cerrano M, Passet M, Vasseur L, Hirsch P, Thomas X, Quentin S, et al. Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC). Blood. 2019; 134(Supplement_1): 2700. DOI: https://doi.org/10.1182/blood-2019-127475

  34. Burnett AK, Russell NH, Hills RK. Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. Blood. 2016;128(3):449-52. DOI: https://doi.org/10.1182/blood-2016-04-712091

  35. DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood 2020; 135(2):85-96. DOI: https://doi.org/10.1182/blood.2019001239

  36. Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125:3878-85

  37. Quintero Y, Hernández C, Romero A, Concepción Y, Macia I, Llerena D et al. Incorporación de las altas dosis de antraciclina en el tratamiento de la leucemia mieloide aguda del adulto. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2019[acceso: 18/12/2019]; 35(1): [aprox. 0 p.]. Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/942

  38. Estey EH, Gale RP, Sekeres MA. New drug in AML: uses and abuses. Leukemia. 2018;32:1479-81. DOI: https://10.1038/s41375-018-0168-Z

  39. Desoutter J, Gay J, Berthon C, Ades L, Gruson B, Geffroy S, et al. Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. Leukemia.2016; 30:1416-8.

  40. Wei AH, Tiong IS. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood. 2017; 130(23):2469-74

  41. Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, et al. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. Leukemia. 2018;32:1621-30 DOI: https://doi.org/10.1038/s41375-018-0129-6

  42. Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, Labarthe A, et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood. 2016;127:2157-60.

  43. Walter RB. Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opin Investig Drugs. 2018;27(4):339-48.

  44. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351(cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018; 36(26):2684-92

  45. Nikanjam M, Capparelli EV, Lancet JE, Louie A, Schiller G. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemother Pharmacol. 2018;81(1):171-8.




2020     |     www.medigraphic.com